Five commercially available insulin-like growth factor I (IGF-I) assays in comparison to the former Nichols Advantage IGF-I in a growth hormone treated population

Krebs, Alexander; Wallaschofski, Henri; Spilcke-Liss, Elisabeth; Kohlmann, Thomas; Brabant, Georg; Völzke, Henry; Nauck, Matthias

doi:10.1515/cclm.2008.349

Cited by 61 publications

(52 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The assays use different antibodies, different sample extraction methods to remove high-affinity binding proteins, and different approaches to calibration (1,2 ). When 5 immunoassay methods were compared to the former gold standard, the Nichols Advantage assay, the slopes of the regression lines varied between 0.527 and 1.00 (3 ). Better interlaboratory agreement of IGF-1 concentrations is needed for clinical and antidoping applications (4 ).…”

confidence: 99%

Interlaboratory Agreement of Insulin-like Growth Factor 1 Concentrations Measured by Mass Spectrometry

Cox¹,

Lopes

Woldemariam

et al. 2014

Clinical Chemistry

View full text Add to dashboard Cite

BACKGROUND:Insulin-like growth factor 1 (IGF-1) 7 is a key mediator of growth hormone (GH) action and a well-characterized biomarker of GH abuse. Current immunoassays for IGF-1 suffer from poor concordance between platforms, which makes comparison of results between laboratories difficult. Although previous work has demonstrated good interlaboratory imprecision of LC-MS/MS methods when plasma is supplemented with purified proteins, the interlaboratory imprecision of an endogenous protein in the nanogram-per-milliliter concentration range has not been reported.

show abstract

confidence: 99%

Interlaboratory Agreement of Insulin-like Growth Factor 1 Concentrations Measured by Mass Spectrometry

Cox¹,

Lopes

Woldemariam

et al. 2014

Clinical Chemistry

View full text Add to dashboard Cite

show abstract

“…However, even when using kits that are calibrated against the same international standard, and the same method to remove IGF-I binding proteins, patient classification in terms of IGF-I categories remains variable (7)(8)(9)(10). We suspected that a potential reason for these discrepancies was the use of different reference values.…”

Section: Introductionmentioning

confidence: 99%

Classification of Patients With GH Disorders May Vary According to the IGF-I Assay

Mavromati¹,

Kuhn

Agostini

et al. 2017

The Journal of Clinical Endocrinology &Amp; Metabolism

View full text Add to dashboard Cite

show abstract

“…After incubation, the content of the tubes was removed and bound radioactivity was measured. The bound radioactivity is directly proportional to the IGF-1 concentration in the sample [19]. …”

Section: Methodsmentioning

confidence: 99%

Study of Primary IGF-1 Deficiency in Egyptian Children with Idiopathic Short Stature

Anwar

Kandeel²,

Mandour³

et al. 2013

Horm Res Paediatr

View full text Add to dashboard Cite

Background/Aims: Primary insulin-like growth factor-1 (IGF-1) deficiency (IGFD) is defined by low levels of IGF-1 without growth hormone (GH) deficiency and absence of secondary causes. The aim of this study was to evaluate IGF-1 in Egyptian children with idiopathic short stature (ISS) and describe patients with IGFD. Methods: This cross-sectional study included 50 children with ISS following up at the Diabetes Endocrine and Metabolism Pediatric Unit at Cairo University Pediatric Hospital. Children were included based on the following criteria: (1) short stature with current height standard deviation score (SDS) ≤-2.5; (2) age between 2 and 9 years in boys and 2 and 8 years in girls, and (3) prepubertal status. Exclusion criteria were: (1) identified cause of short stature and (2) pubertal children. IGF-1-deficient children were defined as children without GH deficiency and with IGF-1 levels below the 2.5th percentile. Results: Among 50 children with ISS, 14 (28%) patients had low IGF-1 levels, consistent with the diagnosis of primary IGFD. When compared with non-IGFD children, IGFD children had lower birth weight SDS (-1.8 vs. -0.7 SDS, p < 0.0001) and lower height SDS (-4.2 vs. -3.1 SDS, p < 0.05) and more delayed bone age (2.6 vs. 1.6 years, p = 0.001). Conclusion: Primary IGF-1 deficiency is found in 28% of children with ISS.

show abstract

Five commercially available insulin-like growth factor I (IGF-I) assays in comparison to the former Nichols Advantage IGF-I in a growth hormone treated population

Abstract: To yield IGF-I determination comparable to the former Nichols IGF-I, either the Siemens or the IDS assay should be applied, and the results should be converted by a linear method transformation. Where a conversion factor is not desired, the DSL assay should be selected.

Cited by 61 publications

References 18 publications

Interlaboratory Agreement of Insulin-like Growth Factor 1 Concentrations Measured by Mass Spectrometry

Interlaboratory Agreement of Insulin-like Growth Factor 1 Concentrations Measured by Mass Spectrometry

Classification of Patients With GH Disorders May Vary According to the IGF-I Assay

Study of Primary IGF-1 Deficiency in Egyptian Children with Idiopathic Short Stature

Contact Info

Product

Resources

About